Anal cancer is a disease in which malignant cancerous cells form in the anal tissue. At Alfa Cytology, we are committed to helping our clients unravel the complexity of these diseases by providing integrated preclinical research solutions.
Introduction to Anal Cancer
Anal cancer incidence and mortality are increasing every year from 1992 to 2022. For example, the American Cancer Society reports 9,760 new cases of anal cancer in the U.S. in 2022, up from 9,440 the year before (2022). In addition, the number of deaths due to anal cancer increases from 1,670 to 1,870 in 2022. And anal cancer is slightly more common in women than men. The increase in cases, coupled with rising mortality rates, highlights the unmet need for therapeutic advances in anal cancer.
Fig.1 Statistical map of incidence and mortality data of anal cancer. (Credit the National Cancer Institute as the source.)
Therapy Development for Anal Cancer
Infection with human papillomavirus (HPV) has been associated with this cancer. The combination of antibody immunotherapy and cancer vaccine is the best therapy in recent research. Vaccination reduces the lifetime risk of anal cancer and may be a cost-effective intervention.
The following table provides a list of ongoing clinical trials in anal cancer.
| Clinical Trial Identifier |
Focus |
Name |
Phase I |
Phase II |
Phase III |
| NCT04046133 |
ICI |
CORINTH |
|
| NCT04230759 |
ICI |
RADIANCE |
|
| NCT04472429 3 |
ICI |
POD1UM-303 |
|
| NCT04166318 |
RT |
DECREASE |
|
| NCT05385250 |
RT |
DACG-I |
|
| NCT05572801 |
ctDNA |
NOAC9 |
|
| NCT03946358 |
ICI, Vaccine |
VolATIL |
|
| NCT04429542 1 |
EGFR, TGFβ |
KEYNOTE-E28 |
|
Our Services
At Alfa Cytology, we are dedicated to providing comprehensive and innovative solutions for all your anal cancer-related needs. Our state-of-the-art preclinical research facilities and specialized team of biologists and scientists are dedicated to conducting groundbreaking in vitro and in vivo studies to explore novel therapeutic approaches, validate potential biomarkers, and uncover the underlying mechanisms of these complex diseases. Our preclinical services encompass a wide range of capabilities, including cell line development, high-throughput screening,
pharmacokinetic and pharmacodynamic evaluations, and advanced animal models.
Modeling Services of Bile Duct Cancer Anal Cancer
Organoids
Derived from human anal tissue samples or pluripotent stem cells.
Optional Species
- Mouse
- Rats
- Zebrafish
- Non-human Primates
At Alfa Cytology, we are committed to the research and study of anal cancer, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. For more information about our anal cancer research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.
For research use only.
Related Services
